AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02502864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care: Cyclophosphamide
Description: Cycle 1: 600 mg/m\^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
Study NCT02502864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Function Assessment of Cancer Therapy (FACT) Surveys
Description: Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
Study NCT03141944 — intervention group
Intervention type: OTHER
Intervention: Starkstein scale of Apathy
Description: The degree of apathy will be evaluated with the Starkstein scale of Apathy
Study NCT01661790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
Study NCT01661790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 30mg,intrapleural administration,each 2 week
Study NCT04017195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
Study NCT01661790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 30mg,intrapleural administration,each 2 week
Study NCT03152942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
Study NCT03152942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
Study NCT03152942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
Study NCT01247311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement
Description: Placebo given orally 3xweek for six months
Study NCT01247311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 5000 IU vitamin D given orally 3xweek for six months
Study NCT01247311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 0.5ug 1,25 vitamin D given orally 3xweek for six months
Study NCT04492566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery
Description: Participants will use the Automated Insulin Delivery (AID) iAPS system for 48-60 hours in a medically supervised session.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy.
Study NCT04812561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bronch™
Description: 2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
Study NCT04812561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
Study NCT01671527 — intervention group
Intervention type: PROCEDURE
Intervention: Transcranial magnetic stimulation (TMS)
Description: We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.
Study NCT03693560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg Oral Tablet
Description: Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.
Study NCT03693560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg Oral Tablet
Description: Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.
Study NCT03693560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride upto 4 mg Oral Tablet
Description: Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet
Study NCT01030666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
Study NCT01030666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
Study NCT01030666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified/simplified papilla preservation flap; scaling
Description: Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
Study NCT01030666 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: modified/simplified papilla preservation flap; scaling
Description: Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
Study NCT01030666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prefgel/Emdogain
Description: When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
Study NCT01030666 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Prefgel/Emdogain
Description: When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
Study NCT01030666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate solution
Description: Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
Study NCT01030666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.12% chlorhexidine gluconate solution
Description: Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
Study NCT01030666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg (if necessary)
Description: 400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
Study NCT01030666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 400 mg (if necessary)
Description: 400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
Study NCT01030666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gluconate gel (if necessary)
Description: If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
Study NCT01030666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% chlorhexidine gluconate gel (if necessary)
Description: If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
Study NCT00254267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 125mg, oral, once a day
Study NCT03409887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraorifice barrier of GIC
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
Study NCT03409887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Base of GIC
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
Study NCT03409887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct composite restoration
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
Study NCT00936728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic nutritional supplementation
Description: Given orally
Study NCT00936728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: white wine
Description: Given orally
Study NCT00936728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00936728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01048346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support Model
Description: Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
Study NCT01202591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Tablet oral twice daily
Study NCT02342418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tedizolid phosphate
Description: Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
Study NCT01909011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active CES
Description: The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
Study NCT01909011 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CES
Description: The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
Study NCT01806662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: Injection of monoclonal antibody against the p40 subunit of IL-12/23
Study NCT01806662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Injection of monoclonal antibody against the p40 subunit of IL-12/23
Study NCT01806662 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo
Study NCT01806662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection of placebo
Study NCT02739178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GSF Intervention
Description: Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
Study NCT03512457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention
Description: Women view an educational poster in changing room, and they receive a brochure.
Study NCT03512457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Intervention
Description: Women view an educational poster in changing room, and they receive a brochure.
Study NCT04066712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 200 mg
Description: Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
Study NCT01202591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Tablet oral once daily
Study NCT01202591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet oral twice daily
Study NCT01557634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Overnight closed-loop insulin delivery
Description: Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
Study NCT01557634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Overnight closed-loop insulin delivery
Description: Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
Study NCT03101111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-CHIK
Description: Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose
Study NCT03101111 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR-vaccine
Description: Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
Study NCT03350269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information provision
Description: Kidney transplant recipients are informed that their donors may be eligible for lost wage reimbursement
Study NCT02805270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medication reconciliation intervention
Description: medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
Study NCT00483756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Standard of care
Study NCT00483756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
Study NCT00483756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
Study NCT00835029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole varnish
Description: Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
Study NCT00835029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole troches
Description: The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
Study NCT02113800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (Afinitor®)
Description: Formulation: 10 mg/day Route: oral (tablet)
Study NCT03802058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 40mg/m2 for Injection weekly
Study NCT03802058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=2 for Injection weekly
Study NCT03802058 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy
Description: Thoracic radiation therapy 60-66Gy/30-33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
Study NCT00910507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise counseling
Description: Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
Study NCT00910507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise training
Description: Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
Study NCT02356809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovasculgen
Description: Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
Study NCT00167778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transverse plane rotation adaptor pylon
Description: Potential future practice
Study NCT00167778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid pylon
Description: Current clinical practice
Study NCT03660137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOLLI Localization
Description: All patients will also be implanted with an additional MOLLI seed using a specialized introducer needle. A specialized MOLLI probe will be used to find the magnetic seed during the lumpectomy surgery.
Study NCT00755209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tranexamic acid
Description: Loading 1 gram (\~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (\~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
Study NCT02452931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 45 mg
Description: Subcutaneous injection
Study NCT02989987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Exposure Therapy
Study NCT02989987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support
Description: A local counselors provides social support on demand.
Study NCT05343468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The MapHabit System
Description: The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device.
Study NCT00763503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD 2027
Description: 3µg/g Oily Spray
Study NCT02880696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular stimulation sequence
Description: Vibrotactile stimulation of the right hand with regular intervals and random omissions